« Return to News | Drug Sponsors

Pfizer backs out of pact with Biotica

Thursday, August 4, 2011 11:12 AM

Pfizer has returned the rights to a rapamycin analogue program it has been running to explore the potential of diseases such as multiple sclerosis and lupus to the UK's Biotica Technology, according to PharmaTimes.

The privately-owned group has regained full rights to the program which began after a deal was signed in 2006 with Wyeth (acquired by the US giant in October 2009). Since then, Pfizer has investigated these compounds in several diseases, "and in particular has extensively profiled candidate drugs in MS and systemic lupus erythematosus.”

Biotica says it intends to continue development in these indications but Pfizer is cutting back on its research activities and the project has been terminated. Mary Collins, chief scientific officer at the latter's immunology and autoimmunity research unit, said Pfizer had "enjoyed a productive collaboration with Biotica,” and the decision to return this program was made as part of its portfolio review process.

Edward Hodgkin, Biotica's chief executive, said, "Our compounds are supported by a strong data package generated by Pfizer, and show evidence of meaningful differentiation in diseases with significant unmet need."

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

February 25

Analysts: With market anticipation of Quintiles IPO, other CROs could soon file to go public

National Clinical Trial Network aims to link sponsors, minority patients for trials and access to new therapies

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

March

Sites rate the best
sponsors of 2013
Largest survey response ever puts Biogen Idec, Forest Labs, Bayer at top

As CRO industry
turns 30, a look back
at modest beginnings
Phenomenal growth, strategic partnering highlight evolution
of CROs

Already a subscriber?
Log in to your digital subscription.

Purchase the March issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

February

Sized out of big deals,
mid-tier CROs still thriving
Finding market niches, strategies to stay vital in changing research enterprise

Industry leaders embrace disruptive innovations
Despite resistance to change, many exploring data sharing, open-source collaboration

Already a subscriber?
Log in to your digital subscription.

Purchase the February issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.